Cell Therapies are pleased to announce that they are partnering with Chimeric Therapeutics to explore the potential to manufacture Chimeric’s CAR-T assets in Australia.
Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies.
Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.
“This is great progress for Chimeric and aims to provide Australian patients with access to our first in class CAR T clinical trials,” said Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics.
“We are very pleased to work with Chimeric to bring their innovative CAR T products to Australian cancer patients in need,” said Dr Bev Menner, Chief Executive Office of Cell Therapies.
The full version of the press release can be found at: ASX:CHM – Chimeric partnering with Cell Therapies Australia (chimerictherapeutics.com)
